In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Journal of Antimicrobial Chemotherapy - Tập 55 Số 6 - Trang 965-973 - 2005
David L. Paterson1, Flávia Rossi, Fernando Baquero2, Po‐Ren Hsueh3, Gail L. Woods4, Vilas Satishchandran5, Theresa A. Snyder5, Charlotte M. Harvey5, Hedy Teppler5, Mark J. DiNubile5, Joseph W. Chow5
1University of Pittsburgh Medical Center, Pittsburgh PA USA
2Hospital Ramon y Cajal, Madrid, Spain
3National Taiwan University Hospital, Taipei, Taiwan
4ARUP Laboratories and University of Utah, Salt Lake City, UT, USA;
5Merck Research Laboratories, West Point, PA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Felmingham D, Grüneberg RN. A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother1996; 38 (Suppl. A): 1–57.

Pfaller MA, Jones RN, Doern GV et al. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Chemother1998; 42: 1762–70.

Turner PJ, Greenhalgh JM, Edwards JR et al. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int J Antimicrob Agents1999; 13: 117–25.

Jones RN, Masterton R. Determining the value of antimicrobial surveillance programs. Diagnostic Microbiology and Infectious Disease2001; 41: 171–5.

Felmingham D. The need for antimicrobial resistance surveillance. J Antimicrob Chemother2002; 50 (Suppl. S1): 1–7.

National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically—Sixth Edition: Approved Standard M7-A6. Villanova, PA, USA: NCCLS, 2003.

National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing—Thirteenth Informational Supplement. Supplemental Tables M100-S13. Villanova, PA, USA: NCCLS, 2003.

Cornaglia G, Hryniewicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect2004; 10: 349–83.

Mazuski JE, Sawyer RG, Nathens AB et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect2002; 3: 161–73.

Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis2003; 37: 997–1005.

Stürenburg E, Mack D. Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect2003; 47: 273–95.

Thompson KS. Controversies about extended-spectrum and AmpC β-lactamases. Emerg Infect Dis2001; 7: 333–6.

Komatsu M, Aihara M, Shimakawa K et al. Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae-producing, extended-spectrum β-lactamases isolated in Japan. Diagn Microbiol Infect Dis2003; 46: 125–30.

Stürenburg E, Sobottka I, Noor D et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother2004; 54: 134–8.

Queenan AM, Foleno B, Gownley C et al. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol2004; 42: 269–75.

Decré D, Burghoffer B, Gautier V et al. Outbreak of multi-resistant Klebsiella oxytoca involving strains with extended-spectrum β-lactamases and strains with extended-spectrum activity of the chromosomal β-lactamase. J Antimicrob Chemother2004; 54: 881–8.

Valverde A, Coque TM, Sanchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol2004; 42: 4769–75.

Cantón R, Oliver A, Coque TM et al. Epidemiology of extended-spectrum β-lactamase-producing Enterobacter isolates in a Spanish hospital during a 12-year period. J Clin Microbiol2002; 40: 1237–43.

Levison ME, Mailapur YV, Pradhan SK et al. Regional occurrence of plasmid-mediated SHV-7, an extended-spectrum β-lactamase, in Enterobacter cloacae in Philadelphia teaching hospitals. Clin Infect Dis2002; 35: 1551–4.

Schwaber MJ, Raney PM, Rasheed JK et al. Utility of NCCLS guidelines for identifying extended-spectrum β-lactamases in non-Escherichia coli and non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol2004; 42: 294–8.

Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies—what are we missing? Nat Rev Microbiol2004; 2: 979–83.

Finch RG. Antibiotic resistance: a view from the prescriber. Nat Rev Microbiol2004; 2: 989–99.